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897Value of CMR for the Differential Diagnosis
of Cardiac MassesABSTRACTOBJECTIVES The goal of this study was to evaluate the diagnostic value of CMR features for the differentialdiagnosis of cardiac masses.BACKGROUND Differentiation of cardiac tumors and thrombi and differentiation of benign from malignantcardiac neoplasms is often challenging but important in clinical practice. Studies assessing the value of cardiac magnetic
resonance (CMR) in this regard are scarce.METHODS We reviewed the CMR scans of patients with a deﬁnite cardiac thrombus or tumor. Mass charac-teristics on cine, T1-weighted turbo spin echo (T1w-TSE) and T2-weighted turbo spin echo (T2w-TSE), contrast ﬁrst-pass
perfusion (FPP), post-contrast inversion time (TI) scout, and late gadolinium enhancement (LGE) sequences were
analyzed.RESULTS There were 84 thrombi, 17 benign tumors, and 25 malignant tumors in 116 patients. Morpho-logically, thrombi were smaller (median area 1.6 vs. 8.5 cm2; p < 0.0001), more homogeneous (99% vs.
46%; p < 0.0001), and less mobile (13% vs. 33%; p ¼ 0.007) than tumors. Hyperintensity compared with
normal myocardium on T2w-TSE, FPP, and LGE were more common in tumors than in thrombi (85% vs. 42%,
70% vs. 4%, and 71% vs. 5%, respectively; all p < 0.0001). A pattern of hyperintensity/isointensity (compared
with normal myocardium) with short TI and hypointensity with long TI was very frequent in thrombi (94%), rare
in tumors (2%), and had the highest accuracy (95%) for the differentiation of both entities. Regarding the
characterization of neoplastic masses, malignant tumors were larger (median area 11.9 vs. 6.3 cm2; p ¼ 0.006)
and more frequently exhibited FPP (84% vs. 47%; p ¼ 0.03) and LGE (92% vs. 41%; p ¼ 0.001). The ability
of CMR features to distinguish benign from malignant neoplasms was moderate, with LGE showing the highest
accuracy (79%).CONCLUSIONS CMR features demonstrated excellent accuracy for the differentiation of cardiac thrombifrom tumors and can be helpful for the distinction of benign versus malignant neoplasms. (J Am Coll Cardiol Img
2014;7:896–905) © 2014 by the American College of Cardiology Foundation.A lthough cardiac tumors are rare entities (esti-mated prevalence at autopsy of 0.02% to2.3%, and 0.15% in echocardiographic series)
(1), their morbidity and mortality rates are high (2).
Surgical removal is the treatment option in most
cases, although satisfactory results occur only in
benign types (3). Thrombi have a higher prevalence,
ranging between 3% and 25% (4) and 2% and 50%
(5–7) in patients with atrial ﬁbrillation and left ven-
tricular systolic dysfunction, respectively, and justify
anticoagulation to prevent embolic events (8,9).
Hence, proper differentiation among these entities
remains imperative because both prognosis and ther-
apeutic approach vary substantially.
Transthoracic 2-dimensional echocardiography
is the most common imaging technique used for
cardiac mass evaluation (10), but it is operatordependent, offers poor tissue characterization, and
has acoustic window restrictions in a subset of pa-
tients. Transesophageal and 3-dimensional echocar-
diography may overcome some of these limitations
(11,12). Computed tomography is also useful for the
evaluation of tumors and thrombi (13), although at
the expense of radiation exposure. As opposed to
these modalities, cardiac magnetic resonance (CMR)
has excellent contrast resolution that allows for su-
perior soft tissue characterization. The combined
evaluation of morphology, composition, and perfu-
sion makes CMR a useful tool in the assessment of
cardiac masses (14–18). However, studies testing the
accuracy of CMR in this regard are scarce and have
relatively small sample sizes (19–22). The aim of the
present study was to determine the ability of CMR
features of cardiac masses to differentiate thrombus
TABLE 1 Baseline
Male
Age, yrs
Weight, kg
Atrial ﬁbrillation
GFR, ml/min/1.73 m2
Hypertension
Hyperlipidemia
Diabetes
Smoking history
Family history of CA
Previous MI
Previous stroke or em
Previous coronary re
History of malignanc
Anticoagulation ther
>1 CMR scan
Other imaging techn
LVEF, %
Myocardial scar
Pericardial effusion
Values are n/N (%) or m
CAD ¼ coronary artery
ABBR EV I A T I ON S
AND ACRONYMS
CMR = cardiac magnetic
resonance
FPP = ﬁrst-pass perfusion
LGE = late gadolinium
enhancement
T1w-TSE = T1-weighted turbo
spin echo
T2w-TSE = T2-weighted turbo
spin echo
TI = inversion time
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898from tumor and benign from malignant
neoplasms in a larger population.
METHODS
We retrospectively reviewed consecutive
CMR examinations performed in patients
with a deﬁnite mass in the heart (including
the aortic and pulmonary roots) from
January 2005 to March 2013 at Mount Sinai
Hospital, New York. Deﬁnite thrombus was
deﬁned as a noninﬁltrating structure thatfulﬁlled any of the following classic criteria: 1) adja-
cent to an akinetic myocardial segment (often
infarcted) or central venous catheter (without clinical
signs or symptoms of infection); 2) located in the
atrial appendage in patients with documented atrial
ﬁbrillation; 3) a signiﬁcant size reduction occurred
with anticoagulation therapy and conﬁrmed on
follow-up imaging; and 4) pathological conﬁrmation.SEE PAGE 906A mass was considered a deﬁnite tumor when it
did not meet any of the aforementioned criteria and
fulﬁlled any of the following: 1) was inﬁltrative
(deﬁned as ill-deﬁned borders from normal myocar-
dium and/or invasion of multiple cardiac or extra-
cardiac structures); 2) had typical features of myxomaPatient Characteristics
Thrombus
(n ¼ 77)
Tumor
(n ¼ 39) p V
52/77 (68) 17/39 (44) 0
58  15 60  15 0
77  17 79  16 0
10/75 (13) 3/39 (8) 0
82  28 94  37 0
44/77 (57) 18/38 (47) 0
38/77 (49) 13/38 (34) 0
23/77 (30) 9/38 (24) 0
23/77 (30) 12/38 (32) 0
D 14/77 (18) 5/38 (13) 0
45/76 (59) 1/39 (3) <0
bolic event 7/73 (10) 4/37 (11) 0
vascularization 19/77 (25) 3/39 (8) 0
y 15/77 (20) 18/39 (46) 0
apy 50/70 (71) 11/34 (32) <0
10/77 (13) 5/39 (13) 0
ique 65/76 (86) 33/38 (87) 0
36  16 60  8 <0
51/73 (70) 2/39 (5) <0
15/77 (20) 14/39 (36) 0
ean  SD.
disease; CMR ¼ cardiac magnetic resonance; GFR ¼ glomerular ﬁltration rate(noninﬁltrating lesion attached to the left aspect of
the fossa ovalis), septal lipomatosis (located in the
interatrial septum with evident signal intensity
reduction on a fat saturation black-blood sequence),
or cyst (well circumscribed, spherical or ovoid
shape, and high signal intensity on a T2-weighted
sequence); and 3) had a pathological diagnosis.
Tumors were classiﬁed as malignant or benign on
the basis of histology when available or otherwise on
imaging characteristics different from the factors
tested in the study: inﬁltrating neoplasms were
considered malignant, whereas noninﬁltrating tu-
mors with typical features of myxoma, septal lip-
omatosis, or cyst were classiﬁed as benign (Online
Figure 1). Clinical charts were reviewed for de-
mographic and medical data collection. In patients
undergoing surgery or biopsy, macroscopic and his-
tological ﬁndings were also recorded.
CARDIAC MAGNETIC RESONANCE. CMR studies
were performed on a 1.5-T (82%; Magnetom Sonata
or Magnetom Avanto, Siemens Medical Solutions,
Erlangen, Germany) or a 3.0-T (18%; Ingenuity,
Philips Healthcare, Best, the Netherlands) magnets
by using dedicated phased-array surface coils as
receivers. Sequences were acquired during end-
expiratory breath holds with electrocardiographic
or pulse gating. Our typical protocol includes cine
and black-blood imaging before contrast, followedalue
Benign Tumor
(n ¼ 16)
Malignant Tumor
(n ¼ 23) p Value
.013 4/16 (25) 13/23 (57) 0.051
.85 60  11 61  18 0.9
.61 83  15 75  16 0.13
.37 2/16 (13) 1/23 (4) 0.58
.39 79  57 97  35 0.54
.32 9/15 (60) 9/23 (39) 0.21
.12 8/15 (53) 5/23 (22) 0.045
.49 5/15 (33) 4/23 (17) 0.44
.85 3/15 (20) 9/23 (39) 0.29
.5 4/15 (27) 1/23 (4) 0.069
.0001 0/16 (0) 1/23 (4) 0.50
.84 3/14 (21) 1/23 (4) 0.14
.028 2/16 (13) 1/23 (4) 0.56
.03 2/16 (13) 16/23 (70) <0.0001
.0001 4/11 (36) 7/23 (30) 0.99
.98 1/16 (6) 4/23 (17) 0.63
.92 13/15 (87) 20/23 (87) 0.62
.0001 60  8 59  8 0.57
.0001 1/16 (6) 1/23 (4) 0.41
.054 2/16 (13) 12/23 (52) 0.011
; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction.
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899by ﬁrst-pass perfusion (FPP), inversion time (TI)
scout, and late gadolinium enhancement (LGE)
imaging. Cine images were acquired in all patients
and LGE sequences in 95% and 100% of patients
with thrombi and tumors, respectively. T1-weighted
turbo spin echo (T1w-TSE), T2-weighted turbo spin
echo (T2w-TSE), FPP, and TI scout sequences were
performed more frequently in tumors (100%, 98%,
98%, and 98%, respectively) than thrombi (36%,
54%, 62%, and 74%; p # 0.001 for all). The mean
contrast dose was 0.18  0.03 mmol/kg of gado-
pentetate dimeglumine. Average scanning time was
w45 min.
Because the objective of the study was to test the
ability of CMR for tissue characterization, we did not
evaluate the accuracy of inﬁltration, mass location, or
ﬁndings in other structures (i.e., myocardial infarc-
tion, pericardial effusion), all of which have shown
value in the differential diagnosis of cardiac masses
(16,21,23). Speciﬁc mass imaging features that were
analyzed included:
1. Visualization before contrast administration.
2. Morphology (scored as homogeneous or hetero-
geneous); size, expressed as average diameter
(maximum plus minimum diameters dividedThrombus Inclusion CriteriaA
13: adjacent to an akinetic segment + change in size under ACT
4: adjacent to an akinetic segment + pathological confirmation
3: adjacent to a central catheter + change in size under ACT
1: located in an atrial appendage + change in size under ACT
Adjacent to an akinetic segment
Adjacent to a central catheter
Pathological confirmation
Change in size under ACT
Located in an atrial appendage
> 1 Criteria
45; 53%
21; 25%
4; 5%
2; 2%
3; 4%
9; 11%
FIGURE 1 Distribution of Inclusion Criteria
(A) Thrombus inclusion criteria. (B) Tumor inclusion criteria. *3 lymphom
nomas, 2 lung carcinomas, and 1 lymphoma. ACT ¼ anticoagulation theby 2) and maximal area; and motility (presence
or absence) on cine or black-blood images as
appropriate.
3. Signal intensity on T1w-TSE, T2w-TSE sequences
assessed qualitatively as hypointense/isointense or
hyperintense in reference to normal myocardium.
4. Vascularization on FPP imaging after a bolus of a
gadolinium-based contrast agent on a saturation-
recovery fast gradient-echo sequence.
5. Post-contrast signal intensity, compared with
the normal myocardium, on a dedicated TI scout
(“Look-Locker”) sequence. The TI that nulled the
normal myocardium was considered the reference
to classify other TIs as short or long. Adhering to
previous studies (7), a pattern of hyperintensity/
isointensity with short TI and hypointensity with
long TI was deﬁned as typical for thrombus.
6. Post-contrast T1 time-derived from T1 mapping
in the TI scout using speciﬁc software. Only those
masses with sufﬁcient size and/or image quality
were analyzed.
7. Presence of LGE on an inversion-recovery
gradient-echo sequence.
A single investigator reviewed all CMR examina-
tions and subsequently reanalyzed 20 cases for15; 36%
Pathological Confirmation + Infiltrative
- 5 metastases*
- 1 pleomorphic sarcoma
- 1 leiomyosarcoma
- 1 hamartoma
- 2 unclassified benign tumors
3 myxomas
4 septal lipomatosis
1 cyst
Tumor Inclusion CriteriaB
Pathological Confirmation +
Typical Location and CMR Features
- 4 myxomas
- 1 cyst
5 metastases†
1 pleomorphic sarcoma
1 fibroelastoma
Pathological confirmation
Infiltrative
Typical location and CMR features
> 1 Criteria
7; 17%
12; 28%
8; 19%
as, 1 multiple myeloma, and 1 liposarcoma. †2 hepatocellular carci-
rapy; CMR ¼ cardiac magnetic resonance.
TABLE 2 Speciﬁc CMR Features of Cardiac Masses
Thrombus
(n ¼ 84)
Tumor
(n ¼ 42) p Value
Benign Tumor
(n ¼ 17)
Malignant Tumor
(n ¼ 25) p Value
Pre-contrast visualization 65/84 (77) 42/42 (100) 0.001 17/17 (100) 25/25 (100) NA
Multiple* 7/77 (9) 3/39 (8) 0.8 1/16 (6) 2/23 (9) 0.99
Median diameter, cm 1.6 (1.1–2.3) 3.4 (2.4–4.9) <0.0001 2.7 (1.6–3.5) 4.3 (2.6–5.7) 0.003
Median area, cm2 1.6 (0.7–3.3) 8.5 (4.4–20.3) <0.0001 6.3 (1.8–10.7) 11.9 (5.6–33.4) 0.006
Homogeneous 83/84 (99) 19/41 (46) <0.0001 6/17 (35) 13/24 (54) 0.23
Motility 11/84 (13) 14/42 (33) 0.007 7/17 (41) 7/25 (28) 0.37
T1w-TSE hyperintensity 5/30 (17) 9/42 (21) 0.62 5/17 (29) 4/25 (16) 0.45
T2w-TSE hyperintensity 19/45 (42) 35/41 (85) <0.0001 13/17 (77) 22/24 (92) 0.21
FPP (þ) 2/52 (4) 28/40 (70) <0.0001 7/15 (47) 21/25 (84) 0.03
LGE (þ) 4/80 (5) 30/42 (71) <0.0001 7/17 (41) 23/25 (92) 0.001
Typical TI scout pattern† 58/62 (94) 1/41 (2) <0.0001 1/16 (6) 0/25 (0) 0.39
Post-contrast T1 time, ms‡ 477  139 383  84 0.03 370  63 386  91 0.78
Values are n/N (%), median (range), or mean  SD. *Per-patient analyses. †Hyperintensity/isointensity with short TI and hypointensity with long TI compared with the
normal myocardium. ‡Quantiﬁed on a post-contrast TI scout sequence in 15 thrombi and 15 tumors (3 benign and 12 malignant).
FPP ¼ ﬁrst-pass perfusion; LGE ¼ late gadolinium enhancement; NA ¼ not applicable; T1w-TSE ¼ T1-weighted turbo spin echo; T2w-TSE ¼ T2-weighted turbo spin echo;
TI ¼ inversion time; other abbreviation as in Table 1.
TABLE 3 Accuracy o
Pre-contrast
visualization (–)
Diameter <2.4 cm
Area <4.1 cm2
Homogeneous (þ)
Motility (–)
T2w-TSE
hyperintensity (–)
FPP (–)
LGE (–)
Typical TI scout patter
T1 time $422 ms
*Hyperintensity/isointensit
NPV ¼ negative predicti
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900determination of intraobserver reproducibility. A
second investigator re-evaluated the same 20 cases
for the assessment of interobserver reproducibility.
The study was approved by the local institutional
review board with a waiver of informed consent.
STATISTICAL ANALYSIS. Categorical data were
summarized as frequencies and percentages, and
continuous variables as mean  SD or median and
interquartile ranges. Difference in CMR characteris-
tics between thrombi and tumors and between
benign and malignant tumors were compared by us-
ing the chi-square test, Fisher exact test, the 2-tailed
unpaired Student t test, or the Mann-Whitney test as
appropriate. Diagnostic performance (sensitivity,
speciﬁcity, positive and negative predictive values,
and accuracy) was calculated for each CMR featuref CMR Features for the Diagnosis of Thrombus (Versus Tumor)
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%)
23 100 100 39 48
84 78 88 72 82
89 80 89 79 86
99 54 81 96 84
87 33 72 56 69
58 85 81 65 71
96 70 81 93 85
95 71 86 88 87
n* 94 98 98 91 95
67 80 77 71 73
y with short TI and hypointensity with long TI compared with the normal myocardium.
ve value; PPV ¼ positive predictive value; other abbreviations as in Tables 1 and 2.in which a signiﬁcant difference was found. In the
case of continuous variables, the best cutoff values
were determined by evaluating the coordinate points
of the receiver-operating characteristic curves and
selecting those with the highest accuracy according
to the Youden index (sensitivity þ speciﬁcity – 1).
Intraobserver and interobserver reproducibility for
categorical and continuous variables was assessed
with the kappa and intraclass correlation coefﬁcients,
respectively. Analyses were performed by using SPSS
version 15.0 (IBM SPSS Statistics, IBM Corporation,
Armonk, New York).
RESULTS
PATIENT POPULATION. From an initial group of
146 patients with a suspected cardiac mass, 116 (79%)
had a deﬁnite cardiac mass according to the inclusion
criteria and were included in the ﬁnal analysis.
Baseline characteristics of patient subgroups accord-
ing to mass type are summarized in Table 1.
Compared with patients with a neoplasm, those
with thrombi were more often male and more likely
to have a previous myocardial infarction and coro-
nary revascularization. As expected, patients with
thrombi had lower left ventricular ejection fractions,
increased prevalence of myocardial scars on LGE
sequences, and were more frequently undergoing
anticoagulation therapy. Conversely, a history of
malignancy was more common in patients with tu-
mors. Although pericardial effusion was more prev-
alent in patients with tumors, the difference did not
reach statistical signiﬁcance.
TABLE 4 Accuracy of CMR Features for the Diagnosis of Malignant
(Versus Benign) Tumor
Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%)
Diameter $4.2 cm 52 100 100 61 73
Area $13.4 cm2 48 100 100 57 69
FPP (þ) 84 53 75 67 73
LGE (þ) 92 59 78 83 79
Abbreviations as in Tables 1, 2, and 3.
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901When analyzing the patient characteristics of
those with benign versus malignant tumors, there
was a trend (p ¼ 0.051) for malignancies to occur
more frequently in male subjects. Hyperlipidemia
was more common in benign neoplasms and a history
of malignant disease, and pericardial effusion were
more frequent in malignancies.
CARDIAC MASSES. There were 126 masses: 84
thrombi (67%) and 42 tumors (33%). Neoplasms were
malignant in 25 (60%) cases and benign in 17 (40%).
Seven patients had 2 thrombotic lesions, 2 patients
had 2 malignant neoplasms, and 1 patient had 2
benign tumors. Mass types are listed in Figure 1. More
than one-half of the thrombi were adjacent to an
akinetic myocardial segment, which was infarcted in
39 (87%) of 45 cases. There were 20 (48%) primary
cardiac tumors, 21 (50%) metastases, and 1 malignant
neoplasm of unknown origin (2%).
In terms of location (Online Table 1), most thrombi
(68%) developed in the left ventricle, whereas tu-
mors were more heterogeneously distributed. The
majority of benign tumors (64%) were found either
in the left atrium or the interatrial septum, and 40%
of malignant neoplasms involved multiple cardiac
chambers.
CMR FEATURES. Tables 2 to 4 and Figure 2 summa-
rize CMR ﬁndings for thrombi versus tumors and for
benign versus malignant neoplasms. IntraobserverA
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FIGURE 2 CMR Features of Cardiac Masses
(A) CMR features of thrombi and tumors. (B) CMR features of benign and
gadolinium enhancement; PreCont ¼ pre-contrast visualization; T1-TSE H
T2-weighted turbo spin echo hyperintensity; Typical TI scout ¼ hyperin
long inversion time compared with the normal myocardium; other abbreand interobserver reproducibility of the assessed
CMR parameters was high (Online Table 2).
Thrombus versus tumor. Tumors were signiﬁcantly
larger than thrombi and more frequently visualized
without contrast, whereas thrombi were more fre-
quently homogeneous (Figures 3A and 3B) and less
mobile. No difference in signal intensity was observed
on T1w-TSE; however, hyperintensity compared
with the normal myocardium on T2w-TSE was more
common in tumors (Figures 3C and 3D). FPP and LGE
(Figures 3E to 3J, respectively) were markedly more
frequent in tumors than in thrombi. On the TI scout,
the majority of thrombi (94%) showed a typical
pattern of hyperintensity/isointensity with short TI
and hypointensity with long TI (Figure 4); such a
pattern was exceptional in tumors (2%; p < 0.0001).
The aforementioned parameter showed the highestB
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malignant tumors. *p < 0.05. FPP ¼ ﬁrst-pass perfusion; LGE ¼ late
yper ¼ T1-weighted turbo spin echo hyperintensity; T2-TSE Hyper ¼
tensity/isointensity with short inversion time and hypointensity with
viation as in Figure 1.
FIGURE 3 Differences in CMR Characteristics Between Thrombus and Tumor
(A and B) Cine sequences. Examples of a homogeneous thrombus (A, arrow) and heterogeneous metastatic lung carcinoma (B, arrow) in the
right atrium. (C and D) T2-weighted turbo spin echo (T2w-TSE) sequences. (C) Isointense left ventricular thrombus (arrow). There is a
hyperintense signal from the slow ﬂow surrounding the mass. (D) Hyperintense left atrial myxoma (arrow). (E through H) FPP. (E and G)
Arterial phase. (F and H) Myocardial phase. (E and F) Markedly perfused mass (hamartoma) in the anterior wall of the left ventricle (arrows).
(G and H) Absence of perfusion in a left ventricular apical thrombus (arrows). (I and J) LGE. (I) Presence of LGE in a metastasis of a -
hepatocarcinoma in the right atrium (arrow). (J) Absence of LGE in a right atrial thrombus (arrow). Abbreviations as in Figures 1 and 2.
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902diagnostic accuracy (95%) for the differential diag-
nosis between both types of masses. Adequacy in size
for manual tracing and excessive motility restricted
T1 time measurement to 15 thrombi and 15 tumors.
Post-contrast T1 time was shorter in tumors than in
thrombi. A value $422 ms showed a sensitivity of 67%
and a speciﬁcity of 80% for the diagnosis of thrombus
(area under the receiver-operating characteristic
curve: 0.73 [95% conﬁdence interval: 0.54 to 0.92];
p ¼ 0.03).
Benign versus malignant tumors. Benign tumors were
signiﬁcantly smaller than malignancies. No signiﬁ-
cant difference in black-blood sequences was found
between both types of neoplasms, whereas FPP and
LGE were more frequent in malignant tumors (an
individualized description of each neoplasm feature
is provided in Online Tables 3 and 4). Presence of
LGE was the feature with the highest accuracy
(79%) for the differential diagnosis of both tumor
types.DISCUSSION
The present study demonstrated the diagnostic ac-
curacy of CMR features (the presence of inﬁltration or
other abnormalities such as pericardial effusions was
not considered) for the differential diagnosis of
thrombi versus tumor and benign versus malignant
neoplasms, a critical issue in the clinical management
of patients with a cardiac mass. Our results in 116
patients conﬁrm the ﬁndings of the few previous
studies that had been conducted, which included 22
to 78 patients (19–22).
MOTION, HETEROGENEITY, AND MOBILITY. Most
thrombi (80%) ﬁt the proﬁle of small, homogeneous,
and immobile lesions. Their median diameter of 1.6 cm
and area of 1.6 cm2 are in good agreement with the
median volume of 2.9 cm3 reported by Weinsaft
et al. (7) and mean area of 1.9 cm2 by Mohrs et al. (23).
Of note, widespread use of antithrombotic therapy
in most patients (71% in our series) may have
FIGURE 4 TI Scout
(A) Typical appearance of a thrombus: hyperintensity with short inversion time (TI) (left: arrow), “edged” appearance with a hypointense
border and a central brighter zone with intermediate TI (middle: arrow), and hypointensity with long TI (right: arrow). Underlying apical
infarction is noted (dashed arrows). (B) Left atrial pleomorphic sarcoma showing different patterns in 2 distinct tumor regions: hypointensity
(dashed arrow) and isointensity (arrow) with short TI (left), hyperintensity (dashed arrow), and isointensity (arrow) with an intermediate TI
(middle), and hyperintensity (dashed arrow) and isointensity (arrow) with long TI (right).
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903contributed to this small size. With some exceptions
(e.g., ﬁbroelastomas [which are typically small]), tu-
mors were larger. Furthermore, malignant neoplasms
demonstrated an increased size compared with benign
tumors, a ﬁnding also consistent with previous studies
(24–26). Metastasis, the most frequent malignant
neoplasm, can be particularly large, especially those
that reach the heart through direct extension from
adjacent organs (e.g., lung carcinoma).
Most thrombi (99%) also exhibited a homogeneous
appearance that was found in only one-half of the
tumors, an observation easily explained by the dif-
ference in tissue composition. Although a previous
publication identiﬁed heterogeneous composition as
a sensitive feature of malignancy (19), it has also been
frequently reported in benign neoplasms such as
myxomas (24), and accordingly it did not emerge as a
distinctive parameter between tumor types in our
study. Similarly, motility was more frequent in tu-
mors than in thrombi, but this feature was not help-
ful for the differential diagnosis of benign and
malignant tumors.
SPIN ECHO TISSUE CHARACTERIZATION. We found
no difference in signal intensity on T1w-TSE
imaging between tumors and thrombi, whereashyperintensity on T2w-TSE sequences was far more
common in tumors. Fresh and subacute thrombi can
be hyperintense on T1w and T2w imaging due to red
blood cell lysis and accumulation of paramagnetic
compounds such as deoxyhemoglobin and methe-
moglobin; chronic thrombi (the suspected form in
the majority of our patients) become isointense or
hypointense due to the progressive replacement by
ﬁbrous tissue (27). Similar to chronic thrombi, and
with particular exceptions such as lipomas, most
benign and malignant cardiac tumors tend to be iso-
intense or hypointense on T1w imaging but hyper-
intense on T2w imaging (17).
FIRST-PASS PERFUSION. Most thrombi remained
hypointense, likely due to their avascular nature.
Interestingly, we observed perfusion in 2 (4%)
thrombi, a ﬁnding that may be related to the devel-
opment of neovascularization in the chronic stage
(16). Reﬂecting the sparse vascularization of some
benign lesions (e.g., cysts, lipomas) and the dense
vascularization of the faster growing malignancies,
FFP was more common in the latter, as was also
noted in 1 other series (21).
LATE GADOLINIUM ENHANCEMENT. LGE was absent
in the vast majority of our thrombi population
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904(95%). Therefore, after contrast injection, thrombi
remained hypointense and easy to differentiate from
surrounding bright structures such as blood and/or a
scar (14,15). In our series, 19 of 83 cases were only
detected after contrast administration, which repre-
sents an increase in sensitivity of 23%. Similarly,
Mollet et al. (14) and Weinsaft et al. (7) reported
detection of only 50% and 67%, respectively, of
thrombi before contrast administration. Interest-
ingly, 63 patients (75%) with thrombi had an echo-
cardiogram performed before the CMR scan, and the
mass was only noted in 32 (52%). This is in line with
the series of 106 pathologically conﬁrmed thrombi
reported by Srichai et al. (15), who found high spec-
iﬁcity for all modalities but much lower sensitivity
for transthoracic and transesophageal echocardiog-
raphy than LGE-CMR (23%, 40%, and 88%, respec-
tively). Tumors tended to demonstrate post-contrast
enhancement, and LGE had 87% accuracy in differ-
entiating both entities.
LGE was also much more common in malignant
than in benign tumors (92% vs. 41%). Moreover, the
presence of LGE demonstrated the highest accuracy
(79%) for neoplasm-type differentiation. The combi-
nation of extensive angiogenesis and an expanded
extracellular space (necrosis, inﬂammation) in most
malignant tumors, as well as limited vascularization
of benign neoplasms, likely explains these ﬁndings
(17,18).
TI SCOUT AND T1 MAPPING. At the time of LGE
sequence acquisition, the amount of gadolinium in
the normal myocardium is low but not zero. As
a result, its T1 relaxation time and thus the TI
needed to null the myocardial signal are expected
to be shorter than those of avascular thrombi (7).
Although a previous study described the presence
of hypointensity with long TI as typical of thrombi,
the ability of this feature to differentiate from a
neoplastic mass has not been previously evaluated.
A TI scout pattern showing hyperintensity/
isointensity with short TI and hypointensity with
long TI was present in 94% of our thrombi and
only 1 (2%) tumor (a simple cyst); it had the highest
accuracy (95%) for the differential diagnosis. We have
observed a typical “edged” appearance of thrombi
using intermediate TI, with a dark rim and a central
brighter zone. We speculate that this appearance
may be due to different layers within the thrombus,
with fresher thrombi (and thus shorter T1) in the
periphery.
In addition, we used T1 mapping for objective T1
time quantiﬁcation. As expected, T1 time was shorter
in tumors than in thrombi, although this parameter
did not perform better than visual analysis of the TIscout. This may have been inﬂuenced by multiple
tumor subtypes and small intersubject variations in
contrast dose or image timing. No signiﬁcant differ-
ences were noted between post-contrast T1 times of
malignancies and benign neoplasms, but the small
sample analyzed (3 benign and 12 malignant tumors)
and tumor heterogeneity may have contributed to
this ﬁnding.
STUDY LIMITATIONS. First, the availability of black-
blood, FPP, and TI scout sequences was higher in
tumors than in thrombi. However, they were fre-
quent enough to identify signiﬁcant differences be-
tween thrombi and tumors in all parameters except
for T1w-TSE. Second, the number of tumors included
was low; thus, the absence of signiﬁcant differences
in some CMR features between malignant and benign
types is possibly related to a low statistical power. In
addition, heterogeneity of cardiac tumors precluded
comparison between subtypes. Larger studies that
allow an adequate subgroup assessment would be
desirable; nevertheless, the low prevalence of cardiac
tumors makes this goal difﬁcult to achieve. Third, we
considered that the 12 masses attached to central
venous catheters in the absence of signs of infection
represented thrombi and not vegetations. Of these, 3
had a second additional criterion for thrombus (res-
olution with anticoagulation). Because vegetations
are avascular structures, one would expect them to
behave similarly to thrombi, particularly in contrast-
enhanced sequences, although this remains specula-
tive. Fourth, most CMR features were evaluated from
a qualitative instead of a quantitative point of view
and, consequently, are inﬂuenced by subjectivity.
However, interobserver reproducibility was high, and
this approach reﬂects common clinical practice.
Finally, the T1 time could only be quantiﬁed in a
limited number of patients due to small mass size or
excessive motility in some cases.
CONCLUSIONS
Only 4 (9%) of 46 thrombi demonstrated either
FPP, LGE, or an atypical pattern on the TI scout,
exceptions that may be justiﬁed by the develop-
ment of neovascularization in chronic thrombi. A
combination of negative perfusion, negative LGE, and
a typical thrombus pattern in the TI scout was seen
in 1 (2%) tumor, which corresponded to a cyst,
an avascular structure that can be diagnosed easily
with other sequences such as T2w-TSE imaging.
Absence of FPP and LGE was found in 2 (8%) of 25
malignant tumors, which corresponded to lym-
phomas that showed other malignant features
(inﬁltration).
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905The etiology of a cardiac mass may be uncertain
after routine imaging testing such as echocardiogra-
phy, and it therefore represents a challenge in clin-
ical practice. In addition to features of malignancy
such as inﬁltration or pericardial effusion, a speciﬁc
CMR protocol should focus on: 1) morphological
evaluation (size, homogeneity, and motility) on cine
and black-blood imaging; 2) vascularization assess-
ment with FPP imaging; 3) TI scout pattern; and4) presence of LGE to differentiate benign from
malignant tumors and, particularly, tumors from
thrombi with high accuracy.
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